Das Klinikum

MD, PhD Teresa Amaral

MD, PhD Teresa Amaral

Consultant Medical Oncology Head of Skin Cancer Clinical Trials Center

Kontakt

E-Mail-Adresse: teresa.amaral@med.uni-tuebingen.de

Klinik / Institut / Zentrum

  • Skin Cancer - Melanoma
  • Clinical trials Phase I-IV
  • Investigator Initiated Trials
  • Translational research
  • 1998-2000Pharmaceutical Sciences studies - Pharmacy Faculty Lisbon University
  • 2000-2006Medical Degree – Medicine Faculty Lisbon University and Portuguese Air Force Academy
  • 2002-2003Lecturer for normal anatomy and neuroanatomy - Medicine Faculty Lisbon University
  • 2006-2008General Internship - General Training in Internal Medicine, General Surgery, Gynecology, Pediatrics and Primary Care Medicine – Hospital Center Lisbon North (CHLN) – Hospital Pulido Valente, Lisbon
  • 2008-2009Collaboration with Evidence Based Medicine Study Center - Lisbon (Centro de Estudos de Medicina Baseados na Evidência (CEMBE))
  • 2008-2014Medical Oncology Internship – CHLN - Lisbon
  • 2008-2014Sub-investigator in clinical trials: skin cancer and ovarian cancer – CHLN Lisbon
  • 2011-2014MD at Medical Oncology Unit Lusíadas Hospital - Lusíadas Hospital – Lisbon
  • 20123 months fellowship (October – December) at Skin Cancer Center in Tuebingen - Prof. Dr. med Claus Garbe working group (WG)
  • 2013European Society of Medical Oncology (ESMO) Medical Oncology Examination Amsterdam
  • 2012-2013Lecturer in the Coimbra University Medicine Ph.D. program
  • 2013Lecturer in the Lisbon University Medicine master’s program
  • 2014Board certificate - Medical Oncology – Portuguese Medical Association
  • 2016-2021MD/PhD student at Skin Cancer Center - Tuebingen University, Prof. Claus Garbe WG
  • 2018German Approbation at Medical Association of Baden-Württemberg (Ärztekammer Baden-Württemberg)
  • 2018-currentMedical lead of the Biobank from the Dermato-oncology Department
  • 2021PhD Thesis – Magna cum Laude – Nova Medical School Lisbon
  • 2022Board Certificate - Internal medicine, Hematology and Oncology – German Medical Association
  • 2018-2022Elected and nominated - Member of the Portuguese Young Oncologists Group
  • 2019By competitive selection - Allumna of the European Society of Medical Oncology (ESMO) Leaders Generation Program (LGP)
  • 2019-currrentBy invitation - Member of the ESMO magnitude of clinical benefit scale (ESMO-MCBS) working group
  • 2019-2022By invitation - Member of the ESMO clinical research observatory (ECRO) task force
  • 2019-currentBy invitation - ESMO faculty member for the Melanoma faculty 2019-2023
  • 2020-2022By invitation - Member of the ESMO social media WG
  • 2020-2023Elected and nominated - Chair of the ESMO Young Oncologists Committee (YOC)
  • 2021-currentNominated - Mentor from the ESMO YOC virtual mentorship program
  • 2023-currentNominated - Chair of the ESMO Leadership Development Committee
  • 2023-currentNominated - Subject editor ESMO clinical practice guidelines for melanoma and other skin cancers
  • 2022-currentHead of the Skin Cancer Clinical Trials Center University of Tübingen
  • 2004 - Best student Award: “Adido de Defesa e Aeronáutico Dos Estados Unidos da América 2003-2004” – Portuguese Air Force Academy
  • 2005 - Best student Award: “Spadino Dell’Academia Aeronautica – Il Capo di Stato Maggiore dell’Areronautica Millitare Itlaiana – 2004-2005”
  • 2006 - Best student Award Portuguese Air Force Academy: “Chefe de Estado Maior da Força Aérea – 2006-2007” – Portuguese Air Force Academy
  • 2020 - 1st MAYA (Melanoma Award for Young Academics)
  • 2022 - ASCO Merit award
  • Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma.Váraljai R, Zimmer L, Al-Matary Y, Kaptein P, Albrecht LJ, Shannan B, Brase JC, Gusenleitner D, Amaral T, Wyss N, Utikal J, Flatz L, Rambow F, Reinhardt HC, Dick J, Engel DR, Horn S, Ugurel S, Sondermann W, Livingstone E, Sucker A, Paschen A, Zhao F, Placke JM, Klose JM, Fendler WP, Thommen DS, Helfrich I, Schadendorf D, Roesch A.Nat Cancer. 2023 Jul 31. doi: 10.1038/s43018-023-00610-2. Online ahead of print.PMID: 37525015
  • EGFR expression is associated with relapse in a melanoma cohort receiving adjuvant PD-1-based immunotherapy.Amaral T, Pop OT, Chatziioannou E, Sinnberg T, Niessner H, Zhao J, Ring SS, Joerger M, Schroeder C, Armeanu-Ebinger S, Cozzio A, Leiter U, Thomas I, Jochum W, Garbe C, Forchhammer S, Levesque M, Mangana J, Hölzel M, Dummer R, Schürch CM, Forschner A, Flatz L.J Am Acad Dermatol. 2023 Jul 22:S0190-9622(23)02392-7. doi: 10.1016/j.jaad.2023.06.057. Online ahead of print.PMID: 37487833 No abstract available.
  • Prognosis in stage II melanoma of the head and neck depends on the histological subtype.Jasper S, Keim U, Leiter U, Amaral T, Flatz L, Forschner A.J Dtsch Dermatol Ges. 2023 Jul 23. doi: 10.1111/ddg.15164. Online ahead of print.PMID: 37485634
  • Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastases.Chatziioannou E, Roßner J, Aung TN, Rimm DL, Niessner H, Keim U, Serna-Higuita LM, Bonzheim I, Kuhn Cuellar L, Westphal D, Steininger J, Meier F, Pop OT, Forchhammer S, Flatz L, Eigentler T, Garbe C, Röcken M, Amaral T, Sinnberg T.EBioMedicine. 2023 Jul;93:104644. doi: 10.1016/j.ebiom.2023.104644. Epub 2023 Jun 7.PMID: 37295047 Free PMC article.
  • Early decrease of blood myeloid-derived suppressor cells during checkpoint inhibition is a favorable biomarker in metastatic melanoma.Gaißler A, Bochem J, Spreuer J, Ottmann S, Martens A, Amaral T, Wagner NB, Claassen M, Meier F, Terheyden P, Garbe C, Eigentler T, Weide B, Pawelec G, Wistuba-Hamprecht K.J Immunother Cancer. 2023 Jun;11(6):e006802. doi: 10.1136/jitc-2023-006802.PMID: 37286306 Free PMC article.
  • Neoadjuvant immunotherapy for melanoma is now ready for clinical practice.Garbe C, Dummer R, Amaral T, Amaria RN, Ascierto PA, Burton EM, Dreno B, Eggermont AMM, Hauschild A, Hoeller C, Kaufmann R, Lebbe C, Mandala M, Menzies AM, Moreno D, Michielin O, Nathan P, Patel SP, Robert C, Schadendorf D, Lorigan PC, Scolyer RA, Tawbi HA, van de Wiel BA, Blank C, Long GV.Nat Med. 2023 Jun;29(6):1310-1312. doi: 10.1038/s41591-023-02336-1.PMID: 37193799 No abstract available.
  • Features and Long-Term Outcomes of Stage IV Melanoma Patients Achieving Complete Response Under Anti-PD-1-Based Immunotherapy.Chatziioannou E, Leiter U, Thomas I, Keim U, Seeber O, Meiwes A, Boessenecker I, Gonzalez SS, Torres FM, Niessner H, Sinnberg T, Forschner A, Flatz L, Amaral T.Am J Clin Dermatol. 2023 May;24(3):453-467. doi: 10.1007/s40257-023-00775-7. Epub 2023 May 4.PMID: 37142875 Free PMC article.
  • Identification of stage I/II melanoma patients at high risk for recurrence using a model combining clinicopathologic factors with gene expression profiling (CP-GEP).Amaral T, Sinnberg T, Chatziioannou E, Niessner H, Leiter U, Keim U, Forschner A, Dwarkasing J, Tjien-Fooh F, Wever R, Flatz L, Eggermont A, Forchhammer S.Eur J Cancer. 2023 Mar;182:155-162. doi: 10.1016/j.ejca.2022.12.021. Epub 2022 Dec 30.PMID: 36739215
  • Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors.Nuñez NG, Berner F, Friebel E, Unger S, Wyss N, Gomez JM, Purde MT, Niederer R, Porsch M, Lichtensteiger C, Kramer R, Erdmann M, Schmitt C, Heinzerling L, Abdou MT, Karbach J, Schadendorf D, Zimmer L, Ugurel S, Klümper N, Hölzel M, Power L, Kreutmair S, Capone M, Madonna G, Cevhertas L, Heider A, Amaral T, Hasan Ali O, Bomze D, Dimitriou F, Diem S, Ascierto PA, Dummer R, Jäger E, Driessen C, Levesque MP, van de Veen W, Joerger M, Früh M, Becher B, Flatz L.Med. 2023 Feb 10;4(2):113-129.e7. doi: 10.1016/j.medj.2022.12.007. Epub 2023 Jan 23.PMID: 36693381
  • Medical Oncology Education in Europe: Equipping Medical Oncologists to Provide the Best Care for Patients with Cancer.Jordan K, De Azambuja E, Amaral T, Strijbos M, Curigliano G, Lordick F.Oncol Res Treat. 2023;46(3):72-79. doi: 10.1159/000529128. Epub 2023 Jan 13.PMID: 36642069 Review.
  • Career and Professional Development for Young Oncologists.Mair MJ, Cardone C, Connolly L, Kfoury M, Lambertini M, Lim J, Mariamidze E, Matikas A, Pihlak R, Punie K, Oing C, Sánchez-Bayona R, Sobczuk P, Zhu H, Berghoff AS, Amaral T.Oncol Res Treat. 2023;46(3):67-71. doi: 10.1159/000528541. Epub 2022 Dec 6.PMID: 36473447 Review.
  • Real-world outcomes using PD-1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland.Schumann K, Mauch C, Klespe KC, Loquai C, Nikfarjam U, Schlaak M, Akçetin L, Kölblinger P, Hoellwerth M, Meissner M, Mengi G, Braun AD, Mengoni M, Dummer R, Mangana J, Sindrilaru MA, Radmann D, Hafner C, Freund J, Rappersberger K, Weihsengruber F, Meiss F, Reinhardt L, Meier F, Rainer B, Richtig E, Ressler JM, Höller C, Eigentler T, Amaral T, Peitsch WK, Hillen U, Harth W, Ziller F, Schatton K, Gambichler T, Susok L, Maul LV, Läubli H, Debus D, Weishaupt C, Börger S, Sievers K, Haferkamp S, Zenderowski V, Nguyen VA, Wanner M, Gutzmer R, Terheyden P, Kähler K, Emmert S, Thiem A, Sachse M, Gercken-Riedel S, Kaune KM, Thoms KM, Heinzerling L, Heppt MV, Tratzmiller S, Hoetzenecker W, Öllinger A, Steiner A, Peinhaupt T, Podda M, Schmid S, Wollina U, Biedermann T, Posch C.J Eur Acad Dermatol Venereol. 2023 May;37(5):894-906. doi: 10.1111/jdv.18779. Epub 2022 Dec 12.PMID: 36433688
  • Dynamics of Melanoma-Associated Epitope-Specific CD8+ T Cells in the Blood Correlate With Clinical Outcome Under PD-1 Blockade.Gaißler A, Meldgaard TS, Heeke C, Babaei S, Tvingsholm SA, Bochem J, Spreuer J, Amaral T, Wagner NB, Klein R, Meier F, Garbe C, Eigentler TK, Pawelec G, Claassen M, Weide B, Hadrup SR, Wistuba-Hamprecht K.Front Immunol. 2022 Jul 7;13:906352. doi: 10.3389/fimmu.2022.906352. eCollection 2022.PMID: 35874702 Free PMC article.
  • Objective assessment of tumor infiltrating lymphocytes as a prognostic marker in melanoma using machine learning algorithms.Aung TN, Shafi S, Wilmott JS, Nourmohammadi S, Vathiotis I, Gavrielatou N, Fernandez A, Yaghoobi V, Sinnberg T, Amaral T, Ikenberg K, Khosrotehrani K, Osman I, Acs B, Bai Y, Martinez-Morilla S, Moutafi M, Thompson JF, Scolyer RA, Rimm DL.EBioMedicine. 2022 Aug;82:104143. doi: 10.1016/j.ebiom.2022.104143. Epub 2022 Jul 7.PMID: 35810563 Free PMC article.
  • Combination of Whole-Body Baseline CT Radiomics and Clinical Parameters to Predict Response and Survival in a Stage-IV Melanoma Cohort Undergoing Immunotherapy.Peisen F, Hänsch A, Hering A, Brendlin AS, Afat S, Nikolaou K, Gatidis S, Eigentler T, Amaral T, Moltz JH, Othman AE.Cancers (Basel). 2022 Jun 17;14(12):2992. doi: 10.3390/cancers14122992.PMID: 35740659 Free PMC article.
  • Zirkulierende Tumor-DNA (ctDNA) bei der Entdeckung von Rezidiven bei Melanompatienten mit adjuvanter Anti-PD-1-Therapie.Forschner A, Niessner H, Sinnberg T, Eigentler T, Amaral T, Seith F, Garbe C, Biskup S, Battke F.J Dtsch Dermatol Ges. 2022 Jun;20(6):867-871. doi: 10.1111/ddg.14766_g.PMID: 35711040 No abstract available.
  • Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment.Garbe C, Keim U, Amaral T, Berking C, Eigentler TK, Flatz L, Gesierich A, Leiter U, Stadler R, Sunderkötter C, Tüting T, Utikal J, Wollina U, Zimmer L, Zouboulis CC, Ascierto PA, Eggermont AMM, Grob JJ, Hauschild A, Sekulovic LK, Long GV, Luke JJ, Michielin O, Peris K, Schadendorf D, Kirkwood JM, Lorigan PC; Central Malignant Melanoma Registry (CMMR).J Clin Oncol. 2022 Nov 10;40(32):3741-3749. doi: 10.1200/JCO.22.00202. Epub 2022 Jun 16.PMID: 35709414 Free PMC article.
  • European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022.Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Basset-Seguin N, Bastholt L, Bataille V, Del Marmol V, Dréno B, Fargnoli MC, Forsea AM, Grob JJ, Hoeller C, Kaufmann R, Kelleners-Smeets N, Lallas A, Lebbé C, Lytvynenko B, Malvehy J, Moreno-Ramirez D, Nathan P, Pellacani G, Saiag P, Stratigos AJ, Van Akkooi ACJ, Vieira R, Zalaudek I, Lorigan P; European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization for Research and Treatment of Cancer (EORTC).Eur J Cancer. 2022 Jul;170:256-284. doi: 10.1016/j.ejca.2022.04.018. Epub 2022 May 24.PMID: 35623961 Review.
  • European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022.Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Basset-Seguin N, Bastholt L, Bataille V, Del Marmol V, Dréno B, Fargnoli MC, Forsea AM, Grob JJ, Höller C, Kaufmann R, Kelleners-Smeets N, Lallas A, Lebbé C, Lytvynenko B, Malvehy J, Moreno-Ramirez D, Nathan P, Pellacani G, Saiag P, Stratigos AJ, Van Akkooi ACJ, Vieira R, Zalaudek I, Lorigan P; European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization for Research and Treatment of Cancer (EORTC).Eur J Cancer. 2022 Jul;170:236-255. doi: 10.1016/j.ejca.2022.03.008. Epub 2022 May 12.PMID: 35570085 Review.
  • Circulating tumor DNA (ctDNA) in the detection of relapse in melanoma patients with adjuvant anti-PD-1 therapy.Forschner A, Niessner H, Sinnberg T, Eigentler T, Amaral T, Seith F, Garbe C, Biskup S, Battke F.J Dtsch Dermatol Ges. 2022 Jun;20(6):867-871. doi: 10.1111/ddg.14766. Epub 2022 May 12.PMID: 35555861 No abstract available.
  • TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy.Eckardt J, Schroeder C, Martus P, Armeanu-Ebinger S, Kelemen O, Gschwind A, Bonzheim I, Eigentler T, Amaral T, Ossowski S, Rieß O, Flatz L, Garbe C, Forschner A.J Cancer Res Clin Oncol. 2023 Feb;149(2):833-840. doi: 10.1007/s00432-022-03939-w. Epub 2022 Feb 22.PMID: 35192052 Free PMC article.
  • Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy.Bochem J, Zelba H, Spreuer J, Amaral T, Wagner NB, Gaissler A, Pop OT, Thiel K, Yurttas C, Soffel D, Forchhammer S, Sinnberg T, Niessner H, Meier F, Terheyden P, Königsrainer A, Garbe C, Flatz L, Pawelec G, Eigentler TK, Löffler MW, Weide B, Wistuba-Hamprecht K.J Immunother Cancer. 2021 Dec;9(12):e003439. doi: 10.1136/jitc-2021-003439.PMID: 34933966 Free PMC article.
  • Association between Immune-Related Adverse Events and Survival in 319 Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry.Serna-Higuita LM, Amaral T, Forschner A, Leiter U, Flatz L, Seeber O, Thomas I, Garbe C, Eigentler TK, Martus P.Cancers (Basel). 2021 Dec 6;13(23):6141. doi: 10.3390/cancers13236141.PMID: 34885249 Free PMC article.
  • A Machine learning model trained on dual-energy CT radiomics significantly improves immunotherapy response prediction for patients with stage IV melanoma.Brendlin AS, Peisen F, Almansour H, Afat S, Eigentler T, Amaral T, Faby S, Calvarons AF, Nikolaou K, Othman AE.J Immunother Cancer. 2021 Nov;9(11):e003261. doi: 10.1136/jitc-2021-003261.PMID: 34795006 Free PMC article.
  • Cutaneous melanoma attributable to UVR exposure in Denmark and Germany.Keim U, Gandini S, Amaral T, Katalinic A, Holleczek B, Flatz L, Leiter U, Whiteman D, Garbe C.Eur J Cancer. 2021 Dec;159:98-104. doi: 10.1016/j.ejca.2021.09.044. Epub 2021 Nov 3.PMID: 34742161
  • The ESSO core curriculum committee update on surgical oncology.van der Hage J, Sandrucci S, Audisio R, Wyld L, Søreide K; ESSO core curriculum contributors; Amaral T, Audisio R, Bahadoer V, Beets G, Benstead K, Berge Nilsen E, Bol K, Brandl A, Braun J, Cufer T, Dopazo C, Edhemovic I, Eriksen JG, Fiore M, van Ginhoven T, Gonzalez-Moreno S, van der Hage J, Hutteman M, Masannat Y, Onesti EC, Rau B, De Reijke T, Rubio I, Ruurda J, Sandrucci S, Soreide K, Stattner S, Trapani D, D'Ugo D, Vriens M, Wyld L, Zahl Eriksson AG.Eur J Surg Oncol. 2021 Nov;47(11):e1-e30. doi: 10.1016/j.ejso.2021.10.003. Epub 2021 Oct 13.PMID: 34657781 Review.
  • Early Tumor Size Reduction of at least 10% at the First Follow-Up Computed Tomography Can Predict Survival in the Setting of Advanced Melanoma and Immunotherapy.Almansour H, Afat S, Serna-Higuita LM, Amaral T, Schraag A, Peisen F, Brendlin A, Seith F, Klumpp B, Eigentler TK, Othman AE.Acad Radiol. 2022 Apr;29(4):514-522. doi: 10.1016/j.acra.2021.04.015. Epub 2021 Jun 12.PMID: 34130924
  • Epidemiology of cutaneous melanoma and keratinocyte cancer in white populations 1943-2036.Garbe C, Keim U, Gandini S, Amaral T, Katalinic A, Hollezcek B, Martus P, Flatz L, Leiter U, Whiteman D.Eur J Cancer. 2021 Jul;152:18-25. doi: 10.1016/j.ejca.2021.04.029. Epub 2021 May 29.PMID: 34062483
  • Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy.Turiello R, Capone M, Giannarelli D, Morretta E, Monti MC, Madonna G, Mallardo D, Festino L, Azzaro R, Levesque MP, Imhof L, Weide B, Amaral T, Chevrier M, Sucker A, Rutkowski P, Schadendorf D, Lebbe C, Luke JJ, Wistuba-Hamprecht K, Dummer R, Pinto A, Morello S, Ascierto PA.J Immunother Cancer. 2020 Dec;8(2):e001689. doi: 10.1136/jitc-2020-001689.PMID: 33361405 Free PMC article.
  • An open-label, single-arm, phase II trial of buparlisib in patients with melanoma brain metastases not eligible for surgery or radiosurgery-the BUMPER study.Amaral T, Niessner H, Sinnberg T, Thomas I, Meiwes A, Garbe C, Garzarolli M, Rauschenberg R, Eigentler T, Meier F.Neurooncol Adv. 2020 Oct 22;2(1):vdaa140. doi: 10.1093/noajnl/vdaa140. eCollection 2020 Jan-Dec.PMID: 33305271 Free PMC article.
  • Prognostic significance of an 11-gene RNA assay in archival tissue of cutaneous melanoma stage I-III patients.Gambichler T, Tsagoudis K, Kiecker F, Reinhold U, Stockfleth E, Hamscho R, Egberts F, Hauschild A, Amaral T, Garbe C.Eur J Cancer. 2021 Jan;143:11-18. doi: 10.1016/j.ejca.2020.10.016. Epub 2020 Dec 2.PMID: 33278769
  • Adjuvant and neoadjuvant therapies in melanoma.Lim KHJ, Amaral T.ESMO Open. 2020 Jul;5(4):e000849. doi: 10.1136/esmoopen-2020-000849.PMID: 32616511 Free PMC article.
  • Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts.Garbe C, Keim U, Suciu S, Amaral T, Eigentler TK, Gesierich A, Hauschild A, Heinzerling L, Kiecker F, Schadendorf D, Stadler R, Sunderkötter C, Tüting T, Utikal J, Wollina U, Zouboulis CC, Keilholz U, Testori A, Martus P, Leiter U, Eggermont AMM; German Central Malignant Melanoma Registry and the European Organisation for Research and Treatment of Cancer.J Clin Oncol. 2020 Aug 1;38(22):2543-2551. doi: 10.1200/JCO.19.03034. Epub 2020 Jun 12.PMID: 32530760 Free PMC article.
  • Indirect Comparison of Combined BRAF and MEK Inhibition in Melanoma Patients with Elevated Baseline Lactate Dehydrogenase.Glutsch V, Amaral T, Garbe C, Thoms KM, Mohr P, Hauschild A, Schilling B.Acta Derm Venereol. 2020 Jun 11;100(13):adv00174. doi: 10.2340/00015555-3526.PMID: 32449784 Free PMC article.
  • ESMO Clinical Research Observatory (ECRO): improving the efficiency of clinical research through rationalisation of bureaucracy.Perez-Gracia JL, Awada A, Calvo E, Amaral T, Arkenau HT, Gruenwald V, Bodoky G, Lolkema MP, Di Nicola M, Penel N, Vera R, Sanmamed MF, Douillard JY.ESMO Open. 2020 May;5(3):e000662. doi: 10.1136/esmoopen-2019-000662.PMID: 32393574 Free PMC article. Review.
  • Are Pathogenic Germline Variants in Metastatic Melanoma Associated with Resistance to Combined Immunotherapy?Amaral T, Schulze M, Sinnberg T, Nieser M, Martus P, Battke F, Garbe C, Biskup S, Forschner A.Cancers (Basel). 2020 Apr 28;12(5):1101. doi: 10.3390/cancers12051101.PMID: 32354124 Free PMC article.
  • Primary Resistance to PD-1-Based Immunotherapy-A Study in 319 Patients with Stage IV Melanoma.Amaral T, Seeber O, Mersi E, Sanchez S, Thomas I, Meiwes A, Forschner A, Leiter U, Eigentler T, Keim U, Garbe C.Cancers (Basel). 2020 Apr 22;12(4):1027. doi: 10.3390/cancers12041027.PMID: 32331243 Free PMC article.
  • S3-Leitlinie „Aktinische Keratose und Plattenepithelkarzinom der Haut“ - Kurzfassung, Teil 2: Epidemiologie, chirurgische und systemische Therapie des Plattenepithelkarzinoms, Nachsorge, Prävention und Berufskrankheit.Leiter U, Heppt MV, Steeb T, Amaral T, Bauer A, Becker JC, Breitbart E, Breuninger H, Diepgen T, Dirschka T, Eigentler T, Flaig M, Follmann M, Fritz K, Greinert R, Gutzmer R, Hillen U, Ihrler S, John SM, Kölbl O, Kraywinkel K, Löser C, Nashan D, Noor S, Nothacker M, Pfannenberg C, Salavastru C, Schmitz L, Stockfleth E, Szeimies RM, Ulrich C, Welzel J, Wermker K, Garbe C, Berking C.J Dtsch Dermatol Ges. 2020 Apr;18(4):400-413. doi: 10.1111/ddg.14072_g.PMID: 32291932 German.
  • S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma (cSCC) - short version, part 2: epidemiology, surgical and systemic treatment of cSCC, follow-up, prevention and occupational disease.Leiter U, Heppt MV, Steeb T, Amaral T, Bauer A, Becker JC, Breitbart E, Breuninger H, Diepgen T, Dirschka T, Eigentler T, Flaig M, Follmann M, Fritz K, Greinert R, Gutzmer R, Hillen U, Ihrler S, John SM, Kölbl O, Kraywinkel K, Löser C, Nashan D, Noor S, Nothacker M, Pfannenberg C, Salavastru C, Schmitz L, Stockfleth E, Szeimies RM, Ulrich C, Welzel J, Wermker K, Garbe C, Berking C.J Dtsch Dermatol Ges. 2020 Apr;18(4):400-413. doi: 10.1111/ddg.14072. Epub 2020 Apr 4.PMID: 32247292
  • Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients.Amaral T, Kiecker F, Schaefer S, Stege H, Kaehler K, Terheyden P, Gesierich A, Gutzmer R, Haferkamp S, Uttikal J, Berking C, Rafei-Shamsabadi D, Reinhardt L, Meier F, Karoglan A, Posch C, Gambichler T, Pfoehler C, Thoms K, Tietze J, Debus D, Herbst R, Emmert S, Loquai C, Hassel JC, Meiss F, Tueting T, Heinrich V, Eigentler T, Garbe C, Zimmer L; *German Dermatological Cooperative Oncology Group.J Immunother Cancer. 2020 Mar;8(1):e000333. doi: 10.1136/jitc-2019-000333.PMID: 32221017 Free PMC article.
  • S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma - short version, part 1: diagnosis, interventions for actinic keratoses, care structures and quality-of-care indicators.Heppt MV, Leiter U, Steeb T, Amaral T, Bauer A, Becker JC, Breitbart E, Breuninger H, Diepgen T, Dirschka T, Eigentler T, Flaig M, Follmann M, Fritz K, Greinert R, Gutzmer R, Hillen U, Ihrler S, John SM, Kölbl O, Kraywinkel K, Löser C, Nashan D, Noor S, Nothacker M, Pfannenberg C, Salavastru C, Schmitz L, Stockfleth E, Szeimies RM, Ulrich C, Welzel J, Wermker K, Berking C, Garbe C.J Dtsch Dermatol Ges. 2020 Mar;18(3):275-294. doi: 10.1111/ddg.14048.PMID: 32130773
  • S3-Leitlinie „Aktinische Keratose und Plattenepithelkarzinom der Haut“ - Kurzfassung, Teil 1: Diagnostik, Interventionen bei aktinischen Keratosen, Versorgungsstrukturen und Qualitätsindikatoren.Heppt MV, Leiter U, Steeb T, Amaral T, Bauer A, Becker JC, Breitbart E, Breuninger H, Diepgen T, Dirschka T, Eigentler T, Flaig M, Follmann M, Fritz K, Greinert R, Gutzmer R, Hillen U, Ihrler S, John SM, Kölbl O, Kraywinkel K, Löser C, Nashan D, Noor S, Nothacker M, Pfannenberg C, Salavastru C, Schmitz L, Stockfleth E, Szeimies RM, Ulrich C, Welzel J, Wermker K, Berking C, Garbe C.J Dtsch Dermatol Ges. 2020 Mar;18(3):275-294. doi: 10.1111/ddg.14048_g.PMID: 32130769 German.
  • MDM2, MDM4 and EGFR Amplifications and Hyperprogression in Metastatic Acral and Mucosal Melanoma.Forschner A, Hilke FJ, Bonzheim I, Gschwind A, Demidov G, Amaral T, Ossowski S, Riess O, Schroeder C, Martus P, Klumpp B, Gonzalez-Menendez I, Garbe C, Niessner H, Sinnberg T.Cancers (Basel). 2020 Feb 26;12(3):540. doi: 10.3390/cancers12030540.PMID: 32110946 Free PMC article.
  • European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2019.Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Bastholt L, Bataille V, Del Marmol V, Dréno B, Fargnoli MC, Grob JJ, Höller C, Kaufmann R, Lallas A, Lebbé C, Malvehy J, Middleton M, Moreno-Ramirez D, Pellacani G, Saiag P, Stratigos AJ, Vieira R, Zalaudek I, Eggermont AMM; European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization for Research and Treatment of Cancer (EORTC).Eur J Cancer. 2020 Feb;126:141-158. doi: 10.1016/j.ejca.2019.11.014. Epub 2020 Jan 9.PMID: 31928887
  • European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2019.Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Bastholt L, Bataille V, Del Marmol V, Dréno B, Fargnoli MC, Grob JJ, Höller C, Kaufmann R, Lallas A, Lebbé C, Malvehy J, Middleton M, Moreno-Ramirez D, Pellacani G, Saiag P, Stratigos AJ, Vieira R, Zalaudek I, Eggermont AMM; European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization for Research and Treatment of Cancer (EORTC).Eur J Cancer. 2020 Feb;126:159-177. doi: 10.1016/j.ejca.2019.11.015. Epub 2019 Dec 19.PMID: 31866016
  • Clinical validation of a prognostic 11-gene expression profiling score in prospectively collected FFPE tissue of patients with AJCC v8 stage II cutaneous melanoma.Amaral TMS, Hoffmann MC, Sinnberg T, Niessner H, Sülberg H, Eigentler TK, Garbe C.Eur J Cancer. 2020 Jan;125:38-45. doi: 10.1016/j.ejca.2019.10.027. Epub 2019 Dec 12.PMID: 31838403
  • Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study.Heppt MV, Amaral T, Kähler KC, Heinzerling L, Hassel JC, Meissner M, Kreuzberg N, Loquai C, Reinhardt L, Utikal J, Dabrowski E, Gesierich A, Pföhler C, Terheyden P, Thoms KM, Zimmer L, Eigentler TK, Kirchberger MC, Stege HM, Meier F, Schlaak M, Berking C.J Immunother Cancer. 2019 Nov 13;7(1):299. doi: 10.1186/s40425-019-0800-0.PMID: 31722735 Free PMC article.
  • ESMO-Magnitude of Clinical Benefit Scale (MCBS) group.Amaral T.ESMO Open. 2019 Oct 8;4(5):e000594. doi: 10.1136/esmoopen-2019-000594. eCollection 2019.PMID: 31673431 Free PMC article. No abstract available.
  • Targeting tumor-resident mast cells for effective anti-melanoma immune responses.Kaesler S, Wölbing F, Kempf WE, Skabytska Y, Köberle M, Volz T, Sinnberg T, Amaral T, Möckel S, Yazdi A, Metzler G, Schaller M, Hartmann K, Weide B, Garbe C, Rammensee HG, Röcken M, Biedermann T.JCI Insight. 2019 Oct 3;4(19):e125057. doi: 10.1172/jci.insight.125057.PMID: 31578309 Free PMC article.
  • Peripheral PD-1+CD56+ T-cell frequencies correlate with outcome in stage IV melanoma under PD-1 blockade.Bochem J, Zelba H, Amaral T, Spreuer J, Soffel D, Eigentler T, Wagner NB, Uslu U, Terheyden P, Meier F, Garbe C, Pawelec G, Weide B, Wistuba-Hamprecht K.PLoS One. 2019 Aug 16;14(8):e0221301. doi: 10.1371/journal.pone.0221301. eCollection 2019.PMID: 31419253 Free PMC article.
  • Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study.Forschner A, Battke F, Hadaschik D, Schulze M, Weißgraeber S, Han CT, Kopp M, Frick M, Klumpp B, Tietze N, Amaral T, Martus P, Sinnberg T, Eigentler T, Keim U, Garbe C, Döcker D, Biskup S.J Immunother Cancer. 2019 Jul 12;7(1):180. doi: 10.1186/s40425-019-0659-0.PMID: 31300034 Free PMC article. Clinical Trial.
  • Immunotherapy plus surgery/radiosurgery is associated with favorable survival in patients with melanoma brain metastasis.Amaral T, Tampouri I, Eigentler T, Keim U, Klumpp B, Heinrich V, Zips D, Paulsen F, Gepfner-Tuma I, Skardelly M, Tatagiba M, Tabatabai G, Garbe C, Forschner A.Immunotherapy. 2019 Mar;11(4):297-309. doi: 10.2217/imt-2018-0149. Epub 2019 Jan 4.PMID: 30606066
  • How to use neoadjuvant medical treatment to maximize surgery in melanoma.Amaral T, Tampouri I, Garbe C.Expert Rev Anticancer Ther. 2018 Feb;18(2):121-130. doi: 10.1080/14737140.2018.1421460. Epub 2018 Jan 3.PMID: 29271674 Review.
  • Merkel cell carcinoma: Epidemiology, pathogenesis, diagnosis and therapy.Amaral T, Leiter U, Garbe C.Rev Endocr Metab Disord. 2017 Dec;18(4):517-532. doi: 10.1007/s11154-017-9433-0.PMID: 28916903 Review.
  • Immunotherapy in managing metastatic melanoma: which treatment when?Amaral T, Meraz-Torres F, Garbe C.Expert Opin Biol Ther. 2017 Dec;17(12):1523-1538. doi: 10.1080/14712598.2017.1378640. Epub 2017 Sep 17.PMID: 28891339 Review.
  • Severe hepatitis under combined immunotherapy: Resolution under corticosteroids plus anti-thymocyte immunoglobulins.Spänkuch I, Gassenmaier M, Tampouri I, Noor S, Forschner A, Garbe C, Amaral T.Eur J Cancer. 2017 Aug;81:203-205. doi: 10.1016/j.ejca.2017.05.018. Epub 2017 Jun 20.PMID: 28641200 No abstract available.
  • Non-melanoma skin cancer: new and future synthetic drug treatments.Amaral T, Garbe C.Expert Opin Pharmacother. 2017 May;18(7):689-699. doi: 10.1080/14656566.2017.1316372. Epub 2017 Apr 17.PMID: 28414587 Review.
  • Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO).Morgan G, Lambertini M, Kourie HR, Amaral T, Argiles G, Banerjee S, Cardone C, Corral J, De Mattos-Arruda L, Öztürk A, Petrova M, Poulsen L, Strijbos M, Tyulyandina A, Vidra R, Califano R, de Azambuja E, Garrido Lopez P, Guarneri V, Reck M, Moiseyenko V, Martinelli E, Douillard JY, Stahel R, Voest E, Arnold D, Cardoso F, Casali P, Cervantes A, Eggermont AMM, Eniu A, Jassem J, Pentheroudakis G, Peters S, McGregor K, Rauh S, Zielinski CC, Ciardiello F, Tabernero J, Preusser M.ESMO Open. 2016 Dec 7;1(6):e000107. doi: 10.1136/esmoopen-2016-000107. eCollection 2016.PMID: 28255451 Free PMC article. Review.
  • The mitogen-activated protein kinase pathway in melanoma part I - Activation and primary resistance mechanisms to BRAF inhibition.Amaral T, Sinnberg T, Meier F, Krepler C, Levesque M, Niessner H, Garbe C.Eur J Cancer. 2017 Mar;73:85-92. doi: 10.1016/j.ejca.2016.12.010. Epub 2017 Feb 3.PMID: 28169047 Review.
  • MAPK pathway in melanoma part II-secondary and adaptive resistance mechanisms to BRAF inhibition.Amaral T, Sinnberg T, Meier F, Krepler C, Levesque M, Niessner H, Garbe C.Eur J Cancer. 2017 Mar;73:93-101. doi: 10.1016/j.ejca.2016.12.012. Epub 2017 Feb 3.PMID: 28162869 Review.
  • Acquired resistance mechanisms to immunotherapy.Amaral T, Garbe C.Ann Transl Med. 2016 Dec;4(24):547. doi: 10.21037/atm.2016.12.21.PMID: 28149908 Free PMC article. No abstract available.
  • The safety and efficacy of cobimetinib for the treatment of BRAF V600E or V600K melanoma.Amaral T, Nouri N, Garbe C.Expert Rev Anticancer Ther. 2016 Jul;16(7):705-15. doi: 10.1080/14737140.2016.1192469. Epub 2016 Jun 10.PMID: 27219630 Review.
  • The Treatment of Liver Metastases in Patients with Neuroendocrine Tumors in 2012.Macedo D, Amaral T, Fernandes I, Sousa AR, Costa AL, Távora I, Quintela A, Cortes P, Costa L.ISRN Hepatol. 2013 Feb 14;2013:702167. doi: 10.1155/2013/702167. eCollection 2013.PMID: 27335831 Free PMC article. Review.
  • Castration-resistant prostate cancer: mechanisms, targets, and treatment.Amaral TM, Macedo D, Fernandes I, Costa L.Prostate Cancer. 2012;2012:327253. doi: 10.1155/2012/327253. Epub 2012 Mar 5.PMID: 22530130 Free PMC article.
  • Publikationen
  • ESMO - European Society of Medical Oncology
  • ASCO - American Society of Clinical Oncology
  • SPO - Portuguese Society of Medical Oncology